Targeting the miR-224-5p/PTEN pathway: A previously under-characterized strategy to attenuate mesangial cell injury and predict prognosis in diabetic nephropathy.
文献摘要
Aim To ascertain the expression status and clinical performance of miR-224-5p in diabetic nephropathy (DN), alongside its molecular mechanism of regulating mesangial cell injury by targeting phosphatase and tensin homolog (PTEN). Methods Serum miR-224-5p and PTEN mRNA expression were detected in DN patients. Logistic regression was used to analyze independent risk indexes for the poor clinical outcomes in DN. Functional gain/loss and rescue experiments were performed. Target relationships were validated through dual-luciferase reporter assays. Results Serum miR-224-5p expression was significantly increased in DN patients (P Conclusion Increased miR-224-5p expression may serve as a potential circulating biomarker for predicting eGFR decline in DN patients, but these findings are preliminary and require validation in independent cohorts using standardized exogenous spike-in normalization before clinical application. The independence of this association was only demonstrated for the eGFR decline ≥30% endpoint and not for ESRD due to limited statistical power.